Abstract:OBJECTIVES: Cell-free DNA based non-invasive prenatal testing (NIPT) has been shown with closeto-diagnosis sensitivity and specificity in detecting fetal T21, T18, and T13. Future development of this technology focuses on detection of other chromosomal aneuploidies, and more importantly chromosome copy number variants (CNVs) and single-gene mutations. Validation studies were carried out to demonstrate the feasibility of detecting CNVs and single-gene disease by exploiting the cell-free DNA testing strategy and existing NIPT platforms. METHOD: For testing CNVs, 35 plasma samples with known fetal CNVs (>10 Mb in size) were recruited, together with 1077 plasma samples with normal fetal karyotypes as the control. The samples were blindly tested using the routine NIPT testing pipelines adopted at the clinical laboratories of BGI, and analyzed with the proprietary FCAPS protocol. Results were compared to the karyotyping results to calculate the sensitivity and specificity of the NIPT test. For testing single-gene disease, we developed a unique haplotype-assisted approach which was validated in a Maple Syrup Urine Disease (MSUD) case. In a trio family (father, mother in early pregnancy, and proband), targeted sequencing (180X) of the known genes causing MSUD was used to identify the disease causative mutations in the proband child and parents. At 13 gestational weeks, maternal plasma DNA and genomic DNA of the trio family were tested with a customized array at the sequencing depth of 40X and 20X respectively to retrieve the SNPs information for the purpose of parental haplotypes deduction. Linkage analysis and Hidden Markov Model were then used to construct the fetal genotype and haplotype flanking the MSUD mutation region. RESULTS: For CNV detection, with on average 4–5 M reads per sample and the existing NIPT platforms, we were able to use the FCAPS analytic protocol to identify 32 positive samples in total of 35, and generated 6 false positive cases, leading to overall sensitivity and specificity of 91.4% and 99.4% respectively. False positive rate and false negative rate of the test were 0.56% and 0.28% respectively. We also showed that with an increased sequencing depth, the detection power of the test can be further improved. In the MUSD case, deep targeted sequencing in the trio family identified that the proband child carries a missense mutation and a large deletion on BCKDHA gene, which were inherited from the mother and father respectively. With the SNP markers of the proband and parents, parental haplotype of chromosome 19 in 6148 loci were recovered. After fetal haplotype construction, the same alleles as that of the proband in the causative gene BCKDHA were inherited to the fetus, indicating that the fetus is a MSUD patient. This result was later confirmed by invasive diagnosis, and led to a well-informed decision after post-test counselling. CONCLUSIONS: We demonstrate the successful application of NIPT in detection of CNVs larger than 10 Mb without changing much to the current pipelines of aneuploidy detection. It has the potential to be integrated into the current NIPT test and offer extra benefits to the clinical service. The haplotype-assisted approach we developed requires minimum genetic information to accurately predict fetal condition. It has the clinical potential for noninvasive prenatal diagnosis of single gene disease for family with a proband child and seeks a second healthy child.

EP06.06: Analysis of Copy Number Variations in Fetal Conotruncal Heart Defects Using Low‐coverage Whole Genome Sequencing

Noninvasive detection of chromosomal CNV and single gene disease by massively parallel sequencing of cfDNA

OC26.03: Comparison of the Prevalence of Pathogenic Copy Number Variation in Tetralogy of Fallot and Associated Congenital Heart Defect Diagnosed Between Fetuses and Children

Prevalence of 22q11.2 Microdeletion in Children with Sporadic Non-Syndromic Conotruncal Heart Defects

Expanding the Scope of Non-invasive Prenatal Testing to Detect Fetal Chromosomal Copy Number Variations

Chromosomal Microarray Analysis in Fetuses with Congenital Anomalies of the Kidney and Urinary Tract: A Prospective Cohort Study and Meta‐analysis

Copy Number Variant Analysis for Syndromic Congenital Heart Disease in the Chinese Population.

Genome-wide Copy Number Variant Analysis for Congenital Ventricular Septal Defects in Chinese Han Population

Diagnostic Yield of Whole Exome Data in Fetuses Aborted for Conotruncal Malformations

[Analysis of Genomic Copy Number Variations in Two Unrelated Neonates with 8p Deletion and Duplication Associated with Congenital Heart Disease].

Efficiency of copy number variation sequencing combined with karyotyping in fetuses with congenital heart disease and the following outcomes

Genome-Wide Association Studies of Conotruncal Heart Defects with Normally Related Great Vessels in the United States

Identification of Copy Number Variations Associated with Congenital Heart Disease by Chromosomal Microarray Analysis and Next‐generation Sequencing

Genomic insights into prenatal diagnosis of congenital heart defects: value of CNV-seq and WES in clinical practice

Cell-free DNA Test for Pathogenic Copy Number Variations: A Retrospective Study.

P01.02: Frequency of 22q11 microdeletion syndrome in fetuses with conotruncal heart disease: Poster discussion hub abstracts

Clinical efficiency of simultaneous CNV-seq and whole-exome sequencing for testing fetal structural anomalies

The implication of chromosomal abnormalities in the surgical outcomes of Chinese pediatric patients with congenital heart disease

Detection of copy number variation associated with ventriculomegaly in fetuses using single nucleotide polymorphism arrays

Contribution of Genomic Imbalance in Prenatal Congenital Anomalies of the Kidney and Urinary Tract: A Multi‐Center Cohort Study

High positive predictive value of CNVs detected by clinical exome sequencing in suspected genetic diseases